» Articles » PMID: 22930403

Curcuminoids Exert Glucose-lowering Effect in Type 2 Diabetes by Decreasing Serum Free Fatty Acids: a Double-blind, Placebo-controlled Trial

Overview
Date 2012 Aug 30
PMID 22930403
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

Scope: We previously found that curcuminoids decreased blood glucose and improved insulin resistance by reducing serum free fatty acids (FFAs) and increasing fatty acid oxidation in skeletal muscle of diabetic rats. This study was to investigate whether curcuminoids have beneficial effects on type 2 diabetic patients, and its possible mechanisms.

Methods And Results: Overweight/obese type 2 diabetic patients (BMI ≥ 24.0; fasting blood glucose ≥ 7.0 mmol/L or postprandial blood glucose ≥11.1 mmol/L) were randomly assigned to curcuminoids (300 mg/day) or placebo for 3 months. Bodyweight, glycosylated hemoglobin A1c (HbA1c ,% ), serum fasting glucose, FFAs, lipids, and lipoprotein lipase (LPL) were determined. A total of 100 patients (curcuminoids, n = 50; placebo, n = 50) completed the trial. Curcuminoids supplementation significantly decreased fasting blood glucose (p < 0.01), HbA1c (p = 0.031), and insulin resistance index (HOMA-IR) (p < 0.01) in type 2 diabetic patients. Curcuminoids also led to a significant decrease in serum total FFAs (p < 0.01), triglycerides (P = 0.018), an increase in LPL activity (p < 0.01).

Conclusion: These findings suggest a glucose-lowering effect of curcuminoids in type 2 diabetes, which is partially due to decrease in serum FFAs, which may result from promoting fatty acid oxidation and utilization.

Citing Articles

Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease.

Ciobarca D, Catoi A, Gavrilas L, Banc R, Miere D, Filip L Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006091 PMC: 11859434. DOI: 10.3390/ph18020279.


The Dynamic Role of Curcumin in Mitigating Human Illnesses: Recent Advances in Therapeutic Applications.

Alam M, Jamir Anwar M, Maity M, Azam F, Jaremko M, Emwas A Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770516 PMC: 11679877. DOI: 10.3390/ph17121674.


Curcumin Attenuates Hyperglycemia and Inflammation in Type 2 Diabetes Mellitus: Quantitative Analysis of Randomized Controlled Trial.

Mokgalaboni K, Mashaba R, Phoswa W, Lebelo S Nutrients. 2024; 16(23).

PMID: 39683570 PMC: 11644433. DOI: 10.3390/nu16234177.


Curcumin extract improves beta cell functions in obese patients with type 2 diabetes: a randomized controlled trial.

Yaikwawong M, Jansarikit L, Jirawatnotai S, Chuengsamarn S Nutr J. 2024; 23(1):119.

PMID: 39354480 PMC: 11445938. DOI: 10.1186/s12937-024-01022-3.


Effect of nano-curcumin supplementation on cardiometabolic risk factors, physical and psychological quality of life, and depression in patients with coronary slow flow phenomenon: a randomized double-blind clinical trial.

Soltani M, Hosseinzadeh-Attar M, Rezaei M, Alipoor E, Vasheghani-Farahani A, Yaseri M Trials. 2024; 25(1):515.

PMID: 39085864 PMC: 11290174. DOI: 10.1186/s13063-024-08354-9.